



Market update: Commercial transaction for Veterinary Medical Technology Pipeline

Brisbane (Australia) 23 December 2020: Factor Therapeutics Limited (ASX:FTT) (“Company”) provides an update on timing regarding the potential transaction with USA-based BrainBiosciences Inc., doing business as LONGMILE Veterinary PET Imaging (“LONGMILE”), to acquire products and technologies for companion animal and equine veterinary imaging.

The Company advises that ASX has provided notice that a decision on the Company’s application for in-principle advice is anticipated to be received early in 2021.

By mutual agreement the exclusivity agreement in place between the parties is extended to accommodate the current status.

About LONGMILE Veterinary PET Imaging

LONGMILE Veterinary Imaging is the veterinary division of Brain Biosciences, Inc. (Rockville, Maryland, USA). LONGMILE’s goal is to deliver the power of Position Emission Tomography (PET) to both the equine and companion animal veterinary market by delivering PET imaging devices that meet the unique needs of this specialist imaging market. The πPET® is a high-resolution animal PET imaging system optimised for companion animals and equine veterinary use. The MILE-PET® is the first device for PET imaging of limbs of standing horses without anaesthesia. For more information visit: <https://www.longmilevet.com/>

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or assets described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by the Board of Factor Therapeutics Limited.